门冬氨酸钾镁联合阿替洛尔治疗室性心律失常的效果

Effect of Potassium Magnesium Aspartate Combined with Atenolol in the Treatment of Ventricular Arrhythmia

目的探讨门冬氨酸钾镁联合阿替洛尔对室性心律失常(VA)的治疗价值。方法选择2020年3月至2021年3月柘城中医院接收的80例VA患者为研究对象,根据随机数字表法分为两组,各40例。对照组接受阿替洛尔治疗,观察组接受门冬氨酸钾镁联合阿替洛尔治疗,治疗2个月。比较两组患者治疗2个月时临床疗效;于治疗前、治疗2个月时检测并比较两组24 h心电图指标(室性早搏、短阵室速)、QT离散度[最长QT间期(QT_(max))、最短QT间期(QT_(min))、QT离散度(QTd)]及心功能情况;记录治疗期间两组不良反应发生情况。结果治疗2个月,观察组总有效率高于对照组(P<0.05);治疗2个月,两组室性早搏、短阵室速次数低于治疗前,且观察组低于对照组(P<0.05);治疗2个月,两组QT_(max)、QT_(min)长于治疗前,QTd短于治疗前,且观察组QT_(max)、QT_(min)长于对照组,QTd短于对照组(P<0.05);治疗2个月,两组LVESD低于治疗前,LVEF高于治疗前,观察组LVESD低于对照组,LVEF高于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论门冬氨酸钾镁联合阿替洛尔治疗VA的效果较好,可有效降低VA患者室性早搏、短阵室速次数,改善患者心功能,缓解临床症状。

Objective To explore the clinical value of potassium magnesium aspartate complicated with atenolol in treating ventricular arrhythmia(VA).Methods A total of 80 patients with VA received by Zhecheng Hospital of Traditional Chinese Medicine from March 2020 to March 2021 were selected as the research subjects,they were divided into observation group and control group by random number table method,with 40 cases in each group.The control group was treated with atenolol and the observation group was treated with potassium magnesium aspartate complicated with atenolol,both were treated for 2 months.The clinical efficacy of patients in both groups was compared after 2 months of treatment.Before treatment and 2 months after treatment,24 h ECG indexes(ventricular premature beats,short array ventricular tachycardia),QT dispersion[longest QT interval(QT_(max)),shortest QT interval(QT_(min)),QT dispersion(QTd)]and cardiac function[left ventricular end systolic diameter(LVESD),left ventricular ejection fraction(LVEF)]were detected and compared in both groups.The adverse reactions of both groups during treatment were recorded.Results After 2 months of treatment,the total effective rate in the observation group was higher than that in the control group(P<0.05).After 2 months of treatment,the times of ventricular premature beats and short array ventricular tachycardia in both groups were lower than those before treatment,and the observation group was lower than that in the control group(P<0.05).After 2 months of treatment,QT_(max) and QT_(min) in both groups were longer than those before treatment,and QTd was shorter than that before treatment.In addition,QT_(max) and QT_(min) in the observation group were longer than those in the control group,QTd in the observation group was shorter than that in the control group(P<0.05).After 2 months of treatment,LVESD in both groups was lower and LVEF was higher than before treatment,while LVESD in the observation group was lower and LVEF was higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Potassium magnesium aspartate combined with atenolol is effective in the treatment of VA,which can effectively reduce the times of ventricular premature beats and short array ventricular tachycardia,improve cardiac function and alleviate clinical symptoms of patients.